CB1636

Jurkat FcγRI (CD64) NFAT-Luc

£2,000.00
£2,000.00
Tax included.
Out of Stock

A Jurkat cell line expressing FcγRI (CD64) and an NFAT-luciferase reporter, designed to monitor Fc receptor signalling (ADCP).

FOR RESEARCH USE ONLY

RoukenCells product packaging on a light pink background
Graph comparing Jurkat WT and Jurkat FcyRI (CD64) NFAT-Luc cell populations on a CD64 axis.
Graph showing Luminescence (RLU) on the y-axis against Rituximab concentration (ng/mL) on the x-axis.
  • RoukenCells product packaging on a light pink background
  • Graph comparing Jurkat WT and Jurkat FcyRI (CD64) NFAT-Luc cell populations on a CD64 axis.
  • Graph showing Luminescence (RLU) on the y-axis against Rituximab concentration (ng/mL) on the x-axis.
RoukenCells product packaging on a light pink background
Graph comparing Jurkat WT and Jurkat FcyRI (CD64) NFAT-Luc cell populations on a CD64 axis.
Graph showing Luminescence (RLU) on the y-axis against Rituximab concentration (ng/mL) on the x-axis.
Specification
Target/Receptor
CD64
Aliases
Fc-gamma RI (FcRI), High affinity immunoglobulin gamma Fc receptor I
Fc-gamma RIA (FcgammaRIa)
Uniprot ID
P12314
Receptor Species
Homo sapiens
Response Element
NFAT
Reporter
Firefly Luciferase
Cell Line Background
Jurkat
Target Information and Further Details
This Jurkat cell line stably expresses human Fc-gamma RI (CD64) along with a firefly luciferase reporter driven by NFAT response elements upstream of a minimal promoter. Activation of NFAT can be quantitatively assessed through luciferase activity, providing a robust and sensitive readout for pathway stimulation. Fc-gamma RI (CD64) expression has been confirmed by flow cytometry, and the cell line has been functionally validated in co-culture assays.
Performance Data
Graph comparing Jurkat WT and Jurkat FcyRI (CD64) NFAT-Luc cell populations on a CD64 axis.

Figure 1. CD32a expression profile (orange) compared to wild-type (grey).

Graph showing Luminescence (RLU) on the y-axis against Rituximab concentration (ng/mL) on the x-axis.

Figure 2. ADCC assay with Rituximab (3250 – 0.0001 ng/mL). Jurkat FcγRI (CD64) reporter cells co-cultured with Raji at 5:1 E:T for 24 hrs.

Shipping Details

Supplied as 1 vial of >3 million viable cells.

Specification Sheet

Access detailed product specifications, user guides and technical documentation in PDF format.

Download PDF

Related products

Take a moment to explore selections tailored just for you.

Explore Now